The US Food and Drug Administration (FDA) has granted breakthrough device designation to Roche’s Elecsys pTau217 plasma biomarker assay. The pTau217 assay was developed in collaboration with Eli ...

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s ...

Roche has presented new late breaking data from a prospective trial showing that its Elecsys amyloid plasma panel can rule out Alzheimer’s disease with a high negative predictive value (NPV ...

Roche's Elecsys pTau181 plasma test showed potential to rule out amyloid pathology, with European availability expected by late 2025. With stocks plunging, steady income is key. Tim Melvin & Ryan ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study Data on the Elecsys ... s disease Roche will initiate ...

Results from 604 participants in a multicenter study of Roche’s (RHHBY) Elecsys pTau181 plasma test ... delays to diagnosis and cost to healthcare systems. Roche anticipates tests being ...

Results from 604 participants in a multicentre study of Roche’s Elecsys pTau181 plasma test were presented, demonstrating its potential to accurately rule out amyloid pathology, a hallmark of ...

Results from 604 participants in a multicenter study of Roche’s Elecsys pTau181 plasma test ... delays to diagnosis and cost to healthcare systems. Roche anticipates tests being available ...

Highlights included presentations from the ongoing trontinemab phase Ib/IIa Brainshuttle AD study demonstrating dose-dependent rapid amyloid depletion from the brain and the potential of the Elecsys ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – – Data on the Elecsys® pTau181 plasma test ...